top of page
Friendly Young Doctor_edited.jpg

Medication Assisted Treatment Programs (MATP)

Get A Free Confidential Assessment

Professional, qualified staff.

Personalized care plans.

Get the support you need to make a full recovery.

Call Us:

SUBOXONE Maintenance Program

The Medication Assisted Treatment Program is formerly known as the Suboxone Maintenance Program provided by our agency. Where the Suboxone Maintenance Program only focused on the treatment of Opioid addiction, the Medication Assisted Treatment Program (MATP) addresses both Opioid and Alcohol addiction. MATP is a safe and effective treatment for patients looking to end addiction to opiates and alcohol. Suboxone is the medication specifically used to treatment Opioid dependence in this program.

The Medication Assisted Treatment Program is a 3 to 12 month program with concentrated emphasis on tapering the use of anti-craving medication to achieve no use in conjunction with traditional outpatient substance abuse treatment.

Dr. Moshin Qayyum is the Medical Director for BES Group & Associates/Solutions Plus’ Medication Assisted Treatment Program at Baytown. Dr. Qayyum is certified by the American Board of Psychiatry and Neurology in General Adult Psychiatry and holds a Masters of Business Administration from The University of Chicago. Find more information on Dr. Qayyum at

Individuals are eligible for admission to MATP if they meet the following criteria:

  • DSM-IV criteria for Opioid Dependence

  • TDI Guidelines for Admission into outpatient substance treatment

  • Approved by the Medical Director for this level of care.


Patients who are eligible for this program must be willing to detox from opiates and/or alcohol and adhere to the following:

  • Complete a physical examination conducted by agency’s healthcare professional prior time of admission with payment of assigned fee.

  • Complete intake and screening process with agency’s clinical staff in addition to the Medical Director.

  • Participate in the agency’s eight (8) week program (Intensive Outpatient Program/IOP).

  • Attend weekly individual therapy sessions with assigned therapist.

  • Attend weekly medication monitoring with staff nurse on scheduled day of individual therapy session for refill of prescribed medication (s).

  • Complete a physical examination conducted by Medical Director monthly with payment of assigned fee.

  • Participate in services offered by The Here To Help Program starting on initial visit in addition to community support groups such as Alcoholics Anonymous, Narcotics Anonymous, or other such programs.

  • Submit to random drug screens at the participant’s expense.

  • Participate in Aftercare Program weekly after discharge from eight (8) week program (Intensive Outpatient Program/IOP).


To schedule an appointment, contact our Rehab Facilities at 832-389-2982. Self-pay and all insurance is accepted for this treatment. We are happy to answer any related questions to MATP.

Contact us today! We are standing by to help.

  • Who can take Suboxone?
    The medication is indicated for patients with dependence on pain killers and other opiates if their physician sees appropriate. It is not indicated for patients below the age of 16 and has not been studies in children. Please refer to the manufacturer website for more details.
  • How does it stabilize the patient?
    Once the appropriate dose of Suboxone is established, the individual will remain on this dose until steady blood levels are achieved. The individual and the Medical Director will assess level of care from this point forward.
  • What are the side effects of Suboxone?
    Some side effects of Suboxone include, but are not limited to, constipation, nausea, headache, insomnia and possibly withdrawal syndrome. Respiratory depression can also occur although at a much lower frequency compared to full opiates. Please refer to the manufacturer website for more details.
  • What is the intake process?
    Each individual is given a comprehensive substance dependence assessment, as well as an evaluation of mental status and physical examination. If the individual meets the criteria listed above, they will be switched from their current opioid (heroin, methadone or prescription painkillers) to Suboxone. At the time of induction, the individual will be asked to provide a urine sample to confirm the presence of opioids and possible other drugs. The individual must arrive for the first visit experiencing mild to moderate opioid withdrawal symptoms. Arrangements will be made for the individual to receive their first dose in the office while it is monitored. If necessary, the individual may receive additional medication to reduce withdrawal symptoms. Since an individual’s tolerance and reactions to Suboxone vary, daily appointments may be scheduled and medications will be adjusted until the individual is no longer experiencing withdrawal symptoms or cravings. Urine drug screens are typically required at each visit during this phase of the program. Intake and Induction may both occur at the first visit, depending on the individual’s needs and the doctor’s evaluation.
  • Is Suboxone safe for pregnant women?
    Buprenorphine is not FDA approved for use during pregnancy. Studies to show safety of Buprenorphine for these patients are still lacking and thus methadone is still the first choice for pregnant women. Please refer to the manufacturer website for more details. The information herein is merely the opinion of the author and may not reflect the appropriate nature of the medicine mentioned. For factual description of the medicine please visit the manufacturer website or contact the manufacturer directly.
bottom of page